Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cardiac rehabilitation (CR) is a proven intervention to improve cardiovascular health, offering benefits such as reduced hospital readmission rates, lower mortality rates, and enhanced quality of life ...

Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics ...

Energy Transfer posted first-quarter adjusted EBITDA of $4.9 billion, $400 million above the high end of PitchBook consensus. Management raised the midpoint of full-year EBITDA guidance to $18.4 ...